Skip to main content
Top
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Sarcoma | Research

Bibliometric analysis of Ewing sarcoma from 1993 to 2022

Authors: Guangtao Han, Ting Liu, Pengde Kang

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

Ewing sarcoma has attracted more attention in recent years but has yet to be bibliometrically analyzed. Hence, this study investigated the trend of Ewing sarcoma over the past 30 years with bibliometric analysis.

Methods

Original publications related to Ewing sarcoma were obtained from the Science Citation Index Extension (SCI-E), Social Sciences Citation Index (SSCI), and Web of Science Core Collection (WoSCC) between 1993 and 2022. CiteSpace and VOSviewer were used to extract the countries/regions, institutions, authors, journals, references, and keywords involved in this topic to identify and analyze the research hotspots and trends in this field.

Results

Over the past 30 years (especially in the past five years), the number of articles published on Ewing sarcoma continued to increase, and the most published country was the United States of America (USA). High-frequency keywords included "Ewing sarcoma", "tumor", "family", "bone", "chemotherapy", "expression", "primitive neuroectodermal tumor", "prognostic factors", "children", and "survival rate". According to the analysis of keyword saliency of Ewing sarcoma, we found that "chromosome translocation", "intergroup", "sarcoma", "genomic landscape", and "children oncology group" were emerging research hotspots. The timeline of the cluster map of co-cited literature indicated that the treatment of Ewing sarcoma emerged as a research hotspot.

Conclusion

Researchers' understanding of Ewing sarcoma has improved dramatically over the past 30 years. At present, the research hotspots of Ewing sarcoma mainly focus on the aspects of "chromosome translocation", "intergroup", and "sarcoma". In addition, the timeline of the cluster map of co-cited literature indicated the emergence of the treatment of Ewing sarcoma as a research hotspot.
Literature
1.
go back to reference Chen C, Borker R, Ewing J, et al. Epidemiology, treatment patterns, and outcomes of metastatic soft tissue sarcoma in a community-based oncology network. Sarcoma. 2014;2014: 145764.CrossRefPubMedPubMedCentral Chen C, Borker R, Ewing J, et al. Epidemiology, treatment patterns, and outcomes of metastatic soft tissue sarcoma in a community-based oncology network. Sarcoma. 2014;2014: 145764.CrossRefPubMedPubMedCentral
3.
go back to reference Bedük-Esen ÇS, Gültekin M, Aydın GB, et al. Ewing sarcoma in an infant and review of the literature. Turk J Pediatr. 2019;61(5):760–4.CrossRefPubMed Bedük-Esen ÇS, Gültekin M, Aydın GB, et al. Ewing sarcoma in an infant and review of the literature. Turk J Pediatr. 2019;61(5):760–4.CrossRefPubMed
4.
go back to reference Eaton BR, Claude L, Indelicato DJ, et al. Ewing sarcoma. Pediatr Blood Cancer. 2021;68(Suppl 2): e28355.PubMed Eaton BR, Claude L, Indelicato DJ, et al. Ewing sarcoma. Pediatr Blood Cancer. 2021;68(Suppl 2): e28355.PubMed
5.
go back to reference Zhou F, Zhang T, Jin Y, et al. Worldwide Tinnitus research: a bibliometric analysis of the published literature between 2001 and 2020. Front Neurol. 2022;13: 828299.CrossRefPubMedPubMedCentral Zhou F, Zhang T, Jin Y, et al. Worldwide Tinnitus research: a bibliometric analysis of the published literature between 2001 and 2020. Front Neurol. 2022;13: 828299.CrossRefPubMedPubMedCentral
6.
go back to reference Zhou F, Zhang T, Jin Y, et al. Unveiling the knowledge domain and emerging trends of olfactory dysfunction with depression or anxiety: a bibliometrics study. Front Neurosci. 2022;8(16): 959936.CrossRef Zhou F, Zhang T, Jin Y, et al. Unveiling the knowledge domain and emerging trends of olfactory dysfunction with depression or anxiety: a bibliometrics study. Front Neurosci. 2022;8(16): 959936.CrossRef
7.
go back to reference Zhou F, Zhang T, Jin Y, et al. Developments and emerging trends in the global treatment of chronic Rhinosinusitis from 2001 to 2020: a systematic bibliometric analysis. Front Surg. 2022;9: 851923.CrossRefPubMedPubMedCentral Zhou F, Zhang T, Jin Y, et al. Developments and emerging trends in the global treatment of chronic Rhinosinusitis from 2001 to 2020: a systematic bibliometric analysis. Front Surg. 2022;9: 851923.CrossRefPubMedPubMedCentral
8.
go back to reference Zhou F, Zhang T, Jin Y, et al. Emerging trends and research foci in allergic rhinitis immunotherapy from 2002 to 2021: a bibliometric and visualized study. Am J Transl Res. 2022;14(7):4457–76.PubMedPubMedCentral Zhou F, Zhang T, Jin Y, et al. Emerging trends and research foci in allergic rhinitis immunotherapy from 2002 to 2021: a bibliometric and visualized study. Am J Transl Res. 2022;14(7):4457–76.PubMedPubMedCentral
12.
go back to reference Delattre O, Zucman J, Plougastel B, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature. 1992;359(6391):162–5.CrossRefPubMed Delattre O, Zucman J, Plougastel B, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature. 1992;359(6391):162–5.CrossRefPubMed
13.
go back to reference Boone MA, Taslim C, Crow JC, et al. Identification of a novel FUS/ETV4 fusion and comparative analysis with other Ewing sarcoma fusion proteins. Mol Cancer Res. 2021;19(11):1795–801.CrossRefPubMedPubMedCentral Boone MA, Taslim C, Crow JC, et al. Identification of a novel FUS/ETV4 fusion and comparative analysis with other Ewing sarcoma fusion proteins. Mol Cancer Res. 2021;19(11):1795–801.CrossRefPubMedPubMedCentral
14.
go back to reference Leavey PJ, Laack NN, Krailo MD, et al. Phase III trial adding vincristine-Topotecan-cyclophosphamide to the initial treatment of patients with Nonmetastatic Ewing sarcoma: a children’s oncology group report. J Clin Oncol. 2021;39(36):4029–38.CrossRefPubMedPubMedCentral Leavey PJ, Laack NN, Krailo MD, et al. Phase III trial adding vincristine-Topotecan-cyclophosphamide to the initial treatment of patients with Nonmetastatic Ewing sarcoma: a children’s oncology group report. J Clin Oncol. 2021;39(36):4029–38.CrossRefPubMedPubMedCentral
15.
16.
go back to reference Jagodzińska-Mucha P, Sobczuk P, Mikuła M, et al. Mutational landscape of primary and recurrent Ewing sarcoma. Contemp Oncol (Pozn). 2021;25(4):241–8.PubMed Jagodzińska-Mucha P, Sobczuk P, Mikuła M, et al. Mutational landscape of primary and recurrent Ewing sarcoma. Contemp Oncol (Pozn). 2021;25(4):241–8.PubMed
17.
go back to reference Casey DL, Pitter KL, Wexler LH, et al. TP53 mutations increase radioresistance in rhabdomyosarcoma and Ewing sarcoma. Br J Cancer. 2021;125(4):576–81.CrossRefPubMedPubMedCentral Casey DL, Pitter KL, Wexler LH, et al. TP53 mutations increase radioresistance in rhabdomyosarcoma and Ewing sarcoma. Br J Cancer. 2021;125(4):576–81.CrossRefPubMedPubMedCentral
18.
go back to reference Lee ACW, Nathan SS, Chui CH, Lee KS. Treatment of Ewing sarcoma in children: results from a single centre. Ann Acad Med Singap. 2021;50(10):785–7.CrossRefPubMed Lee ACW, Nathan SS, Chui CH, Lee KS. Treatment of Ewing sarcoma in children: results from a single centre. Ann Acad Med Singap. 2021;50(10):785–7.CrossRefPubMed
19.
go back to reference Jagodzińska-Mucha P, Ługowska I, Świtaj T, et al. The clinical prognostic factors and treatment outcomes of adult patients with Ewing sarcoma. Int J Clin Oncol. 2020;25(11):2006–14.CrossRefPubMed Jagodzińska-Mucha P, Ługowska I, Świtaj T, et al. The clinical prognostic factors and treatment outcomes of adult patients with Ewing sarcoma. Int J Clin Oncol. 2020;25(11):2006–14.CrossRefPubMed
20.
go back to reference van der Woude HJ, Bloem JL, et al. Osteosarcoma and Ewing’s sarcoma after neoadjuvant chemotherapy: value of dynamic MR imaging in detecting viable tumor before surgery. AJR Am J Roentgenol. 1995;165(3):593–8.CrossRefPubMed van der Woude HJ, Bloem JL, et al. Osteosarcoma and Ewing’s sarcoma after neoadjuvant chemotherapy: value of dynamic MR imaging in detecting viable tumor before surgery. AJR Am J Roentgenol. 1995;165(3):593–8.CrossRefPubMed
21.
go back to reference Muratori F, Totti F, Cuomo P, et al. Multimodal treatment in pelvic Ewing sarcoma: a prognostic factor analysis. Surg Technol Int. 2019;34:489–96.PubMed Muratori F, Totti F, Cuomo P, et al. Multimodal treatment in pelvic Ewing sarcoma: a prognostic factor analysis. Surg Technol Int. 2019;34:489–96.PubMed
22.
go back to reference Grohar PJ, Griffin LB, Yeung C, et al. Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells. Neoplasia. 2011;13(2):145–53.CrossRefPubMedPubMedCentral Grohar PJ, Griffin LB, Yeung C, et al. Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells. Neoplasia. 2011;13(2):145–53.CrossRefPubMedPubMedCentral
23.
go back to reference Schöffski P, Blay JY, Ray-Coquard I. Cabozantinib as an emerging treatment for sarcoma. Curr Opin Oncol. 2020;32(4):321–31.CrossRefPubMed Schöffski P, Blay JY, Ray-Coquard I. Cabozantinib as an emerging treatment for sarcoma. Curr Opin Oncol. 2020;32(4):321–31.CrossRefPubMed
24.
go back to reference Harrison DJ, Gill JD, Roth ME, et al. Initial in vivo testing of a multitarget kinase inhibitor, Regorafenib, by the pediatric preclinical testing consortium. Pediatr Blood Cancer. 2020;67(6): e28222.CrossRefPubMedPubMedCentral Harrison DJ, Gill JD, Roth ME, et al. Initial in vivo testing of a multitarget kinase inhibitor, Regorafenib, by the pediatric preclinical testing consortium. Pediatr Blood Cancer. 2020;67(6): e28222.CrossRefPubMedPubMedCentral
Metadata
Title
Bibliometric analysis of Ewing sarcoma from 1993 to 2022
Authors
Guangtao Han
Ting Liu
Pengde Kang
Publication date
01-12-2023
Publisher
BioMed Central
Keyword
Sarcoma
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-10723-7

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine